Skip to content

Investigation of Brain Nitrogen in Partial Ornithine Transcarbamylase Deficiency (OTCD) Using 1 H MRS, DTI, and fMRI

Investigation of Brain Nitrogen in Partial Ornithine Transcarbamylase Deficiency (OTCD) Using 1 H MRS, DTI, and fMRI

Status
Completed
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT01569568
Enrollment
49
Registered
2012-04-03
Start date
2010-09-30
Completion date
2014-08-31
Last updated
2024-03-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Ornithine Transcarbamylase Deficiency

Keywords

Neuroimaging, MRI, Urea cycle, hyperammonemia, cognitive function, ornithine transcarbamylase deficiency

Brief summary

The purpose of this study is to use various types of MRI and cognitive testing to evaluate changes in the brain and cognitive function that occur in subjects with ornithine transcarbamylase deficiency (OTCD) relative to healthy individuals

Detailed description

The overall goal of this project is to characterize metabolic, structural and cognitive changes in OTCD using 1H MRS, DTI, volumetric averaging and fMRI with cognitive testing of executive function measures to validate biomarkers for the effect of HA and its treatment on the brain. The investigators will measure gln and mI in blood and brain (using 1H MRS) in affected participants, and mI in brain in controls, fractional anisotropy as a measure of white matter microstructural damage (by DTI) and brain activation pathways alterations with tasks probing working memory (fMRI). As a secondary outcome measure, the investigators will correlate the findings from neuroimaging with cognitive functioning. This protocol is based on the previous 5104 protocol, now includes children to evaluate the age and stage of disease on these indices in a cohort that is undergoing important developmental events against an age matched typically developing cohort.

Interventions

1H MRS, DTI, FMRI

BEHAVIORALCognitive testing

Behavioral testing

Sponsors

Children's National Research Institute
CollaboratorOTHER
Andrea Gropman
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
7 Years to 60 Years
Healthy volunteers
Yes

Inclusion criteria

Subject inclusion criteria: 1. Patients with OTCD; 2. Age range: 7-60 years 3. Able to undergo neuroimaging safely (i.e. without presence of ferromagnetic devices) 4. Subject has a documented full scale IQ \> 70 Control participant inclusion criteria: 1. Healthy males and females without metabolic disease aged 7-60 years 2. Subject has a documented full scale IQ \> 70

Exclusion criteria

Subject

Design outcomes

Primary

MeasureTime frameDescription
Concentration of Glutamine and MyoinositolBaselineConcentration based on area under curve on 1H Magnetic Resonance Spectroscopy(MRS) and quantitated by LCModel (a method that allows automatic quantitation of spectroscopy data). A metabolite's tissue concentration is related to the integrated amplitude, the area under the curve of the MRS signal, it produces. While MRS signals are usually acquired in the time domain as free induction decays or echoes, they are usually viewed and analyzed in the frequency domain. The frequency domain representation is derived from the acquired time domain data by the Fourier Transform. The protocol we use selects 257 averages. The machine summates the data at each time point to generate one value for the area under the curve. Therefore, we don't have the measurement at each time point. Furthermore, we measured voxels in two different brain areas containing different kinds of brain matter: one voxel was located in posterior cingulate gray matter (PCGM) and the other in parietal white matter (PWM).
Functional Connectivity of Assessed by Resting-state fMRIBaselineInvestigation of differences in functional connectivity of OTCD patients compared to healthy controls, particularly in the default-mode network (DMN) and the set-maintenance network (SMN). Participants underwent a resting-state scan using 3T fMRI. Combining independent component analysis (ICA) and region-of-interest (ROI) analyses, identified the nodes that comprised each network in each group, and assessed internodal connectivity. For each subject, this analysis generated a correlation value, which reflected the strength of functional connectivity between each ROI pair.The correlation r-values were normalized using Fisher's r-to-Z-transform, generating z-scores. The DMN was composed of 1) anterior cingulate/medial prefrontal cortex (ACC/mPFC), 2) posterior cingulate cortex (PCC), and 3) bilateral inferior parietal lobule (IPL). The SMN was composed of 1)ACC, 2) bilateral superior frontal gyrus (SFG), and 3) bilateral anterior insula/frontal operculum (aI/fO).
Fractional Anisotropy Assessed Using DTIBaselineFractional Anisotropy (FA) is a measure of the diffusion asymmetry within a voxel as defined by its eigenvalues. In our study, FA is being used as a measure of white matter integrity, because FA is very sensitive to small microstructural changes.Fractional anisotropy (FA) is a scalar value between zero and one (0-1) that describe anisotropy of a diffusion process. A value of zero means that diffusion is isotropic, i.e. it is unrestricted (or equally restricted) in all directions. A value of one means that diffusion occurs only along one axis and is fully restricted along all other directions.

Secondary

MeasureTime frameDescription
Neuropsychological AssessmentBaselineTesting consisted of the Wechsler Abbreviated Scale of Intelligence (WASI), Comprehensive Trail Making Test (CTMT) (range 17-87), and the Behavioral Rating Inventory of Executive Function (BRIEF) (range GEC: 70-210; BRI:39-82 ; MI:41-92). The WASI includes three measures of intelligence; including, performance IQ (sum of block design and matrices sub scales; range: 40-160), verbal IQ (sum of vocabulary and similarities sub scales; range 40-160), and total IQ (sum of all four subscales; range: 80-320). The CTMT measures simple attention and executive function, it consists of five dot to dots that increase with complexity and difficulty. Higher values indicate better outcomes for all scales.

Participant flow

Participants by arm

ArmCount
Subjects With OTCD
males and females ages 7-60 years with OTCD MRI scanning: 1H MRS, DTI, FMRI Cognitive testing: Neuropsychological testing
20
Healthy Controls
males and females ages 7-60 years who are healthy controls MRI scanning: 1H MRS, DTI, FMRI Cognitive testing: Neuropsychological testing
27
Total47

Withdrawals & dropouts

PeriodReasonFG000FG001
Overall StudyPhysician Decision02

Baseline characteristics

CharacteristicSubjects With OTCDHealthy ControlsTotal
Age, Continuous30.3 years
STANDARD_DEVIATION 19.4
25.8 years
STANDARD_DEVIATION 14.6
28.05 years
STANDARD_DEVIATION 17.02
Sex: Female, Male
Female
17 Participants19 Participants36 Participants
Sex: Female, Male
Male
3 Participants8 Participants11 Participants

Adverse events

Event typeEG000
affected / at risk
EG001
affected / at risk
deaths
Total, all-cause mortality
— / —— / —
other
Total, other adverse events
0 / 200 / 29
serious
Total, serious adverse events
0 / 200 / 29

Outcome results

Primary

Concentration of Glutamine and Myoinositol

Concentration based on area under curve on 1H Magnetic Resonance Spectroscopy(MRS) and quantitated by LCModel (a method that allows automatic quantitation of spectroscopy data). A metabolite's tissue concentration is related to the integrated amplitude, the area under the curve of the MRS signal, it produces. While MRS signals are usually acquired in the time domain as free induction decays or echoes, they are usually viewed and analyzed in the frequency domain. The frequency domain representation is derived from the acquired time domain data by the Fourier Transform. The protocol we use selects 257 averages. The machine summates the data at each time point to generate one value for the area under the curve. Therefore, we don't have the measurement at each time point. Furthermore, we measured voxels in two different brain areas containing different kinds of brain matter: one voxel was located in posterior cingulate gray matter (PCGM) and the other in parietal white matter (PWM).

Time frame: Baseline

Population: Two OTCD patients and one healthy control were excluded due to excessive head motion.

ArmMeasureGroupValue (MEAN)Dispersion
Subjects With OTCDConcentration of Glutamine and MyoinositolConcentration of glutamine in PWM2.61 mMStandard Deviation 1.07
Subjects With OTCDConcentration of Glutamine and MyoinositolConcentration of myoinositol in PWM2.23 mMStandard Deviation 0.84
Subjects With OTCDConcentration of Glutamine and MyoinositolConcentration of glutamine in PCGM5.22 mMStandard Deviation 1.7
Subjects With OTCDConcentration of Glutamine and MyoinositolConcentration of myoinositol in PCGM3.80 mMStandard Deviation 0.8
Healthy ControlsConcentration of Glutamine and MyoinositolConcentration of myoinositol in PCGM4.37 mMStandard Deviation 0.46
Healthy ControlsConcentration of Glutamine and MyoinositolConcentration of glutamine in PWM1.66 mMStandard Deviation 0.93
Healthy ControlsConcentration of Glutamine and MyoinositolConcentration of glutamine in PCGM3.62 mMStandard Deviation 0.91
Healthy ControlsConcentration of Glutamine and MyoinositolConcentration of myoinositol in PWM2.69 mMStandard Deviation 0.48
Comparison: The null hypothesis predicts that the concentration of glutamine is the same for controls and OTCD patients in PCGM.p-value: 0.001t-test, 2 sided
Comparison: The null hypothesis predicts that the concentration of myoinositol is the same for controls and OTCD patients in PCGM.p-value: 0.011t-test, 2 sided
Comparison: The null hypothesis predicts that the concentration of glutamine is the same for controls and OTCD patients in PWM.p-value: 0.004t-test, 2 sided
Comparison: The null hypothesis predicts that the concentration of myoinositol is the same for controls and OTCD patients in PWM.p-value: 0.046t-test, 2 sided
Primary

Fractional Anisotropy Assessed Using DTI

Fractional Anisotropy (FA) is a measure of the diffusion asymmetry within a voxel as defined by its eigenvalues. In our study, FA is being used as a measure of white matter integrity, because FA is very sensitive to small microstructural changes.Fractional anisotropy (FA) is a scalar value between zero and one (0-1) that describe anisotropy of a diffusion process. A value of zero means that diffusion is isotropic, i.e. it is unrestricted (or equally restricted) in all directions. A value of one means that diffusion occurs only along one axis and is fully restricted along all other directions.

Time frame: Baseline

ArmMeasureValue (MEAN)Dispersion
Subjects With OTCDFractional Anisotropy Assessed Using DTI0.25 units on a scaleStandard Deviation 0.003
Healthy ControlsFractional Anisotropy Assessed Using DTI0.3 units on a scaleStandard Deviation 0.008
Primary

Functional Connectivity of Assessed by Resting-state fMRI

Investigation of differences in functional connectivity of OTCD patients compared to healthy controls, particularly in the default-mode network (DMN) and the set-maintenance network (SMN). Participants underwent a resting-state scan using 3T fMRI. Combining independent component analysis (ICA) and region-of-interest (ROI) analyses, identified the nodes that comprised each network in each group, and assessed internodal connectivity. For each subject, this analysis generated a correlation value, which reflected the strength of functional connectivity between each ROI pair.The correlation r-values were normalized using Fisher's r-to-Z-transform, generating z-scores. The DMN was composed of 1) anterior cingulate/medial prefrontal cortex (ACC/mPFC), 2) posterior cingulate cortex (PCC), and 3) bilateral inferior parietal lobule (IPL). The SMN was composed of 1)ACC, 2) bilateral superior frontal gyrus (SFG), and 3) bilateral anterior insula/frontal operculum (aI/fO).

Time frame: Baseline

Population: Resting state data was not acquired for several of our participants (7 controls and 4 patients). Furthermore, 3 OTCD patients were excluded from the analyses due to excessive head motion.

ArmMeasureGroupValue (MEAN)Dispersion
Subjects With OTCDFunctional Connectivity of Assessed by Resting-state fMRIDMN: ACC/mPFC & left IPL connectivity-0.86 z-scoresStandard Deviation 0.7
Subjects With OTCDFunctional Connectivity of Assessed by Resting-state fMRIDMN: ACC/mPFC & PCC connectivity-0.10 z-scoresStandard Deviation 0.7
Subjects With OTCDFunctional Connectivity of Assessed by Resting-state fMRIDMN: ACC/mPFC & right IPL connectivity-0.26 z-scoresStandard Deviation 0.53
Subjects With OTCDFunctional Connectivity of Assessed by Resting-state fMRIDMN: PCC & left IPL connectivity0.69 z-scoresStandard Deviation 0.63
Subjects With OTCDFunctional Connectivity of Assessed by Resting-state fMRIDMN: PCC & right IPL connectivity0.66 z-scoresStandard Deviation 0.42
Subjects With OTCDFunctional Connectivity of Assessed by Resting-state fMRIDMN: left IPL & right IPL connectivity0.75 z-scoresStandard Deviation 0.69
Subjects With OTCDFunctional Connectivity of Assessed by Resting-state fMRISMN: ACC & left aI/fO connectivity0.19 z-scoresStandard Deviation 0.39
Subjects With OTCDFunctional Connectivity of Assessed by Resting-state fMRISMN: ACC & left SFG connectivity0.28 z-scoresStandard Deviation 0.35
Subjects With OTCDFunctional Connectivity of Assessed by Resting-state fMRISMN: ACC & right aI/fO connectivity0.21 z-scoresStandard Deviation 0.3
Subjects With OTCDFunctional Connectivity of Assessed by Resting-state fMRISMN: ACC & right SFG connectivity0.29 z-scoresStandard Deviation 0.37
Subjects With OTCDFunctional Connectivity of Assessed by Resting-state fMRISMN: left aI/fO & left SFG connectivity0.10 z-scoresStandard Deviation 0.35
Subjects With OTCDFunctional Connectivity of Assessed by Resting-state fMRISMN: left aI/fO & right aI/fO connectivity0.71 z-scoresStandard Deviation 0.43
Subjects With OTCDFunctional Connectivity of Assessed by Resting-state fMRISMN: left aI/fO & right SFG connectivity0.05 z-scoresStandard Deviation 0.33
Subjects With OTCDFunctional Connectivity of Assessed by Resting-state fMRISMN: left SFG & right SFG connectivity0.70 z-scoresStandard Deviation 0.43
Subjects With OTCDFunctional Connectivity of Assessed by Resting-state fMRISMN: right aI/fO & left SFG connectivity0.02 z-scoresStandard Deviation 0.22
Subjects With OTCDFunctional Connectivity of Assessed by Resting-state fMRISMN: right aI/fO & right SFG connectivity0.04 z-scoresStandard Deviation 0.26
Healthy ControlsFunctional Connectivity of Assessed by Resting-state fMRISMN: right aI/fO & right SFG connectivity0.27 z-scoresStandard Deviation 0.35
Healthy ControlsFunctional Connectivity of Assessed by Resting-state fMRIDMN: ACC/mPFC & left IPL connectivity0.18 z-scoresStandard Deviation 0.3
Healthy ControlsFunctional Connectivity of Assessed by Resting-state fMRISMN: ACC & right aI/fO connectivity0.44 z-scoresStandard Deviation 0.29
Healthy ControlsFunctional Connectivity of Assessed by Resting-state fMRIDMN: ACC/mPFC & PCC connectivity0.12 z-scoresStandard Deviation 0.4
Healthy ControlsFunctional Connectivity of Assessed by Resting-state fMRISMN: left aI/fO & right SFG connectivity0.11 z-scoresStandard Deviation 0.33
Healthy ControlsFunctional Connectivity of Assessed by Resting-state fMRIDMN: ACC/mPFC & right IPL connectivity0.07 z-scoresStandard Deviation 0.34
Healthy ControlsFunctional Connectivity of Assessed by Resting-state fMRISMN: ACC & right SFG connectivity0.59 z-scoresStandard Deviation 0.23
Healthy ControlsFunctional Connectivity of Assessed by Resting-state fMRIDMN: PCC & left IPL connectivity0.69 z-scoresStandard Deviation 0.31
Healthy ControlsFunctional Connectivity of Assessed by Resting-state fMRISMN: right aI/fO & left SFG connectivity0.25 z-scoresStandard Deviation 0.21
Healthy ControlsFunctional Connectivity of Assessed by Resting-state fMRIDMN: PCC & right IPL connectivity0.64 z-scoresStandard Deviation 0.3
Healthy ControlsFunctional Connectivity of Assessed by Resting-state fMRISMN: left aI/fO & left SFG connectivity0.22 z-scoresStandard Deviation 0.38
Healthy ControlsFunctional Connectivity of Assessed by Resting-state fMRIDMN: left IPL & right IPL connectivity0.70 z-scoresStandard Deviation 0.34
Healthy ControlsFunctional Connectivity of Assessed by Resting-state fMRISMN: left SFG & right SFG connectivity0.68 z-scoresStandard Deviation 0.28
Healthy ControlsFunctional Connectivity of Assessed by Resting-state fMRISMN: ACC & left aI/fO connectivity0.28 z-scoresStandard Deviation 0.41
Healthy ControlsFunctional Connectivity of Assessed by Resting-state fMRISMN: left aI/fO & right aI/fO connectivity0.80 z-scoresStandard Deviation 0.35
Healthy ControlsFunctional Connectivity of Assessed by Resting-state fMRISMN: ACC & left SFG connectivity0.44 z-scoresStandard Deviation 0.29
Comparison: The null hypothesis states predicts no main effects of Group, ROI pair, or Age, suggesting that the connectivity between all DMN nodes is the same across groups.p-value: <0.001ANOVA
Comparison: The null hypothesis predicts that functional connectivity between the ACC/mPFC node and the left IPL node does not differ between groups.p-value: 0.024ANOVA
Comparison: The null hypothesis predicts that functional connectivity between the ACC/mPFC node and the PCC node does not differ between groups.p-value: 0.04ANOVA
Comparison: The null hypothesis predicts that functional connectivity between the ACC/mPFC node and the right IPL node does not differ between groups.p-value: 0.008ANOVA
Comparison: The null hypothesis predicts that functional connectivity between the left IPL node and the right IPL node does not differ between groups.p-value: 0.47ANOVA
Comparison: The null hypothesis predicts that functional connectivity between the PCC node and the left IPL node does not differ between groups.p-value: 0.829ANOVA
Comparison: The null hypothesis predicts that functional connectivity between the PCC node and the right IPL node does not differ between groups.p-value: 0.801ANOVA
Comparison: The null hypothesis states predicts no main effects of Group, ROI pair, or Age, suggesting that the connectivity between all SMN nodes is the same across groups.p-value: <0.001ANOVA
Comparison: The null hypothesis predicts that functional connectivity between the ACC node and the left aI/fO node does not differ between groups.p-value: 0.55ANOVA
Comparison: The null hypothesis predicts that functional connectivity between the ACC node and the left SFG node does not differ between groups.p-value: 0.113ANOVA
Comparison: The null hypothesis predicts that functional connectivity between the ACC node and the right aI/fO node does not differ between groups.p-value: 0.039ANOVA
Comparison: The null hypothesis predicts that functional connectivity between the ACC node and the right SFG node does not differ between groups.p-value: 0.005ANOVA
Comparison: The null hypothesis predicts that functional connectivity between the left aI/fO and the left SFG node does not differ between groups.p-value: 0.426ANOVA
Comparison: The null hypothesis predicts that functional connectivity between the left aI/fO node and the right aI/fO node does not differ between groups.p-value: 0.256ANOVA
Comparison: The null hypothesis predicts that functional connectivity between the left aI/fO and the right SFG node does not differ between groups.p-value: 0.853ANOVA
Comparison: The null hypothesis predicts that functional connectivity between the right aI/fO node and the left SFG node does not differ between groups.p-value: 0.003ANOVA
Comparison: The null hypothesis predicts that functional connectivity between the right aI/fO node and the right SFG node does not differ between groups.p-value: 0.023ANOVA
Secondary

Neuropsychological Assessment

Testing consisted of the Wechsler Abbreviated Scale of Intelligence (WASI), Comprehensive Trail Making Test (CTMT) (range 17-87), and the Behavioral Rating Inventory of Executive Function (BRIEF) (range GEC: 70-210; BRI:39-82 ; MI:41-92). The WASI includes three measures of intelligence; including, performance IQ (sum of block design and matrices sub scales; range: 40-160), verbal IQ (sum of vocabulary and similarities sub scales; range 40-160), and total IQ (sum of all four subscales; range: 80-320). The CTMT measures simple attention and executive function, it consists of five dot to dots that increase with complexity and difficulty. Higher values indicate better outcomes for all scales.

Time frame: Baseline

ArmMeasureGroupValue (MEAN)Dispersion
Subjects With OTCDNeuropsychological AssessmentWASI - Full IQ103.28 units on a scaleStandard Deviation 14.02
Subjects With OTCDNeuropsychological AssessmentBrief - Behavioral Regulation Index (BRI)55.59 units on a scaleStandard Deviation 9.49
Subjects With OTCDNeuropsychological AssessmentWASI - Performance IQ98.5 units on a scaleStandard Deviation 13.14
Subjects With OTCDNeuropsychological AssessmentBrief - Metacognition Index (MI)60.45 units on a scaleStandard Deviation 11.75
Subjects With OTCDNeuropsychological AssessmentTrails - Composite48 units on a scaleStandard Deviation 15
Subjects With OTCDNeuropsychological AssessmentBrief - Global Executive Composite Score (GEC)59.05 units on a scaleStandard Deviation 10.37
Subjects With OTCDNeuropsychological AssessmentWASI - Verbal IQ107.33 units on a scaleStandard Deviation 14.52
Healthy ControlsNeuropsychological AssessmentBrief - Global Executive Composite Score (GEC)46.88 units on a scaleStandard Deviation 7.67
Healthy ControlsNeuropsychological AssessmentWASI - Verbal IQ107.77 units on a scaleStandard Deviation 18.59
Healthy ControlsNeuropsychological AssessmentWASI - Performance IQ112.59 units on a scaleStandard Deviation 14.54
Healthy ControlsNeuropsychological AssessmentWASI - Full IQ111.22 units on a scaleStandard Deviation 16.89
Healthy ControlsNeuropsychological AssessmentTrails - Composite47 units on a scaleStandard Deviation 12
Healthy ControlsNeuropsychological AssessmentBrief - Behavioral Regulation Index (BRI)46.73 units on a scaleStandard Deviation 8.9
Healthy ControlsNeuropsychological AssessmentBrief - Metacognition Index (MI)47.38 units on a scaleStandard Deviation 8.22
p-value: 0.929t-test, 2 sided
p-value: 0.002t-test, 2 sided
p-value: 0.094t-test, 2 sided
p-value: 0.853t-test, 2 sided
p-value: 0.001t-test, 2 sided
p-value: <0.001t-test, 2 sided
p-value: <0.001t-test, 2 sided

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026